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revascularization (IR) on patients with multivessel coronary artery
disease (CAD) who underwent percutaneous coronary intervention
(PCI) or coronary artery bypass graft (CABG).
METHODS From May 2003 to December 2013, a total of 9,582 patients
were analyzed who underwent PCI or CABG for multivessel disease.
Major adverse cardiac event(MACE) including all-cause death,
myocardial infarction and repeat revascularization was compared
between CR and IR group.
RESULTS CR was achieved in 4,423 patients (46.2%); IR was more
common after PCI than CABG (62.1% vs. 39.6%, p<0.001) and IR group
presented with more myocardial infarction than CR group (30.4%
vs.24.6%, p<0.001). During a 10-year follow-up, MACE occurred more
in IR than CR group(44.4% vs. 36.9%, P<0.001). Relative to IR, CR was
associated with lower long-term mortality (adjusted hazard ratio [HR]:
0.876, 95% conﬁdence interval [CI]:0.782 to 0.982, p¼0.023),
myocardial infarction (HR: 0.680, 95% CI: 0.524 to 0.882, p¼0.004),
and repeat revascularization (HR: 0.777, 95% CI: 0.682 to 0.887,
p<0.001). And the survival free from MACE was most beneﬁted in
completely revascularized CABG patients (HR: 0.575, 95% CI: 0.509 to
0.648, p¼0.005).
Table 1. Characteristics of the patients who underwent complete and incomplete revascularizationComplete
(n[4423)Incomplete
(n[5159) p-valueAge (years) 62.76  9.46 63.46  9.79 <0.001
Male 3194 (72.2%) 3815 (73.9%) 0.056Hypertension 2726 (61.6%) 3248 (63.0%) 0.182Diabetes 1697 (38.4%) 1970 (38.2%) 0.867Chronic Kidney Disease (GFR<60) 739 (16.7%) 1009 (19.6%) <0.001Congestive Heart Failure (EF35%) 204 (4.6%) 212 (4.1%) 0.228
Presentation of myocardial infarction 1090 (24.6%) 1568 (30.4%) <0.001Three-vessel disease % 2188 (49.5%) 2940 (57.0%) <0.001Chronic total occlusion % 352 (8%) 286 (5.5%) <0.001Treatment strategy (PCI) 2292 (51.8%) 3760 (72.9%) <0.001Drug eluting stent % 2001 (45.2%) 3217 (62.6%) 0.056CONCLUSIONS In a 10-year follow-up, the achievement of CR in
multivessel CAD was associated with reduced MACE rate, irrespective
of revascularization strategy in the real world.
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BACKGROUND Percutaneous management of ULM disease has gained
guideline acceptance for those with low-to moderate SYNTAX scores.
There are few data to guide best management of restenosis in this
setting. We sought to evaluate the management and outcomes of
restenosis after unprotected left main (ULM) stenting.
METHODS From a total sample of all patients presenting for angiog-
raphy between January 2009 and December 2014 with ULM lesion >
50% (n¼ 1,363), we identiﬁed those with angiographically signiﬁcant
ULM in lesion restenosis (n¼42). The primary end-point was long-
term rate of major adverse cardiac events (MACE) – that is death,
myocardial infarction (MI) or clinically driven target lesion revascu-
larization (TLR).
RESULTS Signiﬁcant ULM lesion restenosis was identiﬁed in 43
patients (3%). The clinical indication for angiography was stable
angina in 33 (78%), non ST-elevation MI in 8 (18%), ST-elevation MI
in 1 (2%) and cardiac arrest in 1 (2%). The initial stenting strategy
was a simple one-stent approach in 24 (56%) and a complex 2-stent
technique in 19 (44%). Details of the initial stent utilized were
available in 37 – drug eluting stent 29 (78 %), bare metal stent
(BMS) 5 (14%) and bioresorbable vascular scaffolds 3 (8%). Reste-
nosis was treated percutaneously in 26 patients (60%) - additional
DES in 22 (84%); balloon angioplasty in 3 (12%); thromboaspiration
in 1 (4%). The remaining 40% were managed surgically. Table 1
shows clinical details by treatment strategy. For those undergoing
repeat PCI a simple 1-stent strategy was employed in 19 (86%).
In-hospital MACE rates was 7% with individual components of
death 4.7% (2) and MI 2.3% (1). After 30þ19 months follow-up
cumulative MACE rate was 23.3% comprising of death in 5 (12%),
MI in 2 (4.7%) and re-TLR in 1 (2.3%). There was no reported
MACE in the surgically managed group.PCI (n[26) CABG (n[17)Age (years) 7413 6313
Male (%) 69 71eGFR (ml/min) 5226 7222
Diabetes (%) 38 47Clinical PresentationStable (n) 18 11NSTEMI (n) 5 6STEMI (n) 2 0Cardiac arrest (n) 1 0Initial strategy1-stent (%) 62 532-stent (%) 38 47CONCLUSIONS Restenosis after ULM stenting presents with a stable
clinical course and can be percutaneously managed with a simple one-
stent strategy in the majority of cases with low repeat TLR rates. The
higher MACE rates for those managed percutaneously may be
explained by operator bias to treat older, more unstable patients with
repeat PCI.
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